LUCENCEINSIGHT™

Multi-Cancer Early Detection

Earlier Cancer Detection for Better Outcomes

78% **Cancer Deaths** Not Covered By **Recommended Screening[1]**

4 Times Higher Survival **With Early Diagnosis[2]**

Introducing LucenceINSIGHT™

LucenceINSIGHT™ is a multi-cancer early detection (MCED) test that screens for the signal of 50 cancers through a simple blood draw. It leverages proprietary technology to amplify and identify signs of ctDNA and viruses in the bloodstream. The advanced sequencing analysis predicts signal localization.

**50 Cancer Types** Detected With **1** Blood Draw

PREDICTED SIGNAL LOCALIZATION ACCURACY[3]
88%

TURNAROUND TIME
12-18 Days

Cancer-associated alterations — **LucenceINSIGHT™**

Symptoms onset

Cancer metastasis — Traditional Screening

The result is cross examined with machine-learning to study the cancer signal profile. Utilizing data from the analysis, the test reports a presence or absence of a cancer signal. A localization signal is also derived and used to predict up to 2 sites where the cancer signal might have originated from ("Predicted Signal Localization"). The report will present the result as Predicted Signal Localization, with an accuracy of 88%.

AmpliMark™ Upgrade (Lucence Mirror Barcodes)

Dual-strand Independent Labelling

5′ | Index | UMI | | UMI | Index | 3′

3′ | | | | | | 5′

LIMIT OF DETECTION[3]
0.05%

SPECIFICITY[3]
99.0%

SENSITIVITY[3]
80.9%

Lucence's ultrasensitive amplicon-based enrichment chemistry offers high sensitivity and specificity for sequencing circulating tumor DNA, with low error rate achieved through mirror barcoding.

Real-world Evidence of LucenceINSIGHT™

1478 Patients validated

264 Healthy individuals enrolled

100% POSITIVE PREDICTED VALUE

Retrospective study shown at ASCO 2023[4] *:

- Reasonable sensitivity and specificity for detection
- Improved tumor of origin prediction accuracy

Real-world experience shown at ESMO Asia 2023[5] *:

- All positive findings confirmed as neoplasms subsequently
- Majority of detected cases not covered by traditional screening guidelines

LUCENCEINSIGHT™

Multi-Cancer Early Detection

Available in the following panels:

There are 50 cancer types covered by **LucenceINSIGHT™ PLUS**. **LucenceINSIGHT™** covers the 12 cancers highlighted in **orange**.

Eye cancer
(Conjunctival melanoma; Uveal melanoma)

Head & Neck
• **Nasopharyngeal cancer**
• **Oropharyngeal cancer**
  (HPV-positive; HPV-negative)
• **Laryngeal cancer**
• **Salivary gland cancer**

• **Non Hodgkin lymphoma**
  (Burkitt's lymphoma; Diffuse large B-cell lymphoma; Lymphoplasmacytic lymphoma)
• **Hairy cell leukemia**

Breast cancer

• **Lung cancer**
  (Non-small cell lung cancer; Small cell lung cancer)
• **Lung neuroendocrine tumors**

Liver cancer

Biliary tract cancer

• **Kidney cancer (clear cell)**
• **Adult Wilms tumor**

Small intestine cancer

• **Cervical cancer**
• **Endometrial cancer**
• **Ovarian cancer**
• **Ovarian germ cell & stromal tumors**
• **Vulvar cancer**

Soft tissue cancer
(Angiosarcoma; Smooth muscle sarcoma)

Esophageal cancer

Thyroid cancer
(Anaplastic; Medullary)

• **Acute myeloid leukemia (AML)**
  (AML, NPM1-mutated; AML, other defined genetic alterations; AML, myelodysplasia-related)
• **Mast cell tumor**
• **Myeloproliferative neoplasms**
• **Myeloma**

Bone cancer

• **Stomach cancer**
• **Stomach neuroendocrine tumors**
• **Gastrointestinal stromal tumor (GIST)**

Adrenal gland cancer

Pancreatic cancer

• **Colorectal cancer**
• **Colorectal neuroendocrine tumors**

Bladder cancer

• **Penile cancer**
• **Prostate cancer**
• **Testis cancer**

Skin cancer
(Melanoma; Non-melanoma)

LUCENCE

Website Facebook Instagram

Noted: The tests are not recommended for use in individuals who are pregnant or have a history of cancer in the past 3 years

REFERENCE   1. GLOBOCAN 2020. 2. American Cancer Society. https://www.cancer.org/cancer.html 3. Data on file. 4. ASCO 2023 Abstract #418936 5. ESMO ASIA Congress 2023 Abstract 415P
*The data of study is collected based on adoption of AmpliMark™ V1.

M6001E-SG-04. January 2024